Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH?

Eur J Nucl Med Mol Imaging. 2004 Jun;31(6):924; author reply 924-5. doi: 10.1007/s00259-004-1502-4. Epub 2004 Mar 18.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adult
  • Carcinoma / blood
  • Carcinoma / drug therapy
  • Carcinoma / metabolism*
  • Carcinoma / radiotherapy
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Iodine Radioisotopes / blood*
  • Iodine Radioisotopes / pharmacokinetics*
  • Iodine Radioisotopes / therapeutic use
  • Kinetics
  • Male
  • Metabolic Clearance Rate / drug effects
  • Middle Aged
  • Neoplasm Recurrence, Local / blood
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / metabolism*
  • Neoplasm Recurrence, Local / radiotherapy
  • Radiopharmaceuticals / pharmacokinetics
  • Radiopharmaceuticals / therapeutic use
  • Radiotherapy Dosage
  • Recombination, Genetic
  • Thyroid Gland / drug effects
  • Thyroid Gland / metabolism*
  • Thyroid Gland / radiation effects
  • Thyroid Neoplasms / blood
  • Thyroid Neoplasms / drug therapy
  • Thyroid Neoplasms / metabolism*
  • Thyroid Neoplasms / radiotherapy
  • Thyrotropin / administration & dosage*

Substances

  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • Thyrotropin